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Background: Measures of clinical utility (net benefit and event free life years) have been recommended in the
assessment of a new predictor in a risk prediction model. However, it is not clear how they relate to the measures
of predictive ability and reclassification, such as the c-statistic and Net Reclassification Improvement (NRI), or how
these measures are affected by differences in mean risk between populations when a fixed cutpoint to define high
risk is assumed.
Methods: We examined the relationship between measures of clinical utility (net benefit, event free life years) and
predictive ability (c-statistic, binary c-statistic, continuous NRI(0), NRI with two cutpoints, binary NRI) using simulated
data and the Framingham dataset.
Results: In the analysis of simulated data, the addition of a new predictor tended to result in more people being
treated when the mean risk was less than the cutpoint, and fewer people being treated for mean risks beyond the
cutpoint. The reclassification and clinical utility measures showed similar relationships with mean risk when the
mean risk was less than the cutpoint and the baseline model was not strong. However, when the mean risk was
greater than the cutpoint, or the baseline model was strong, the reclassification and clinical utility measures
diverged in their relationship with mean risk.
Although the risk of CVD was lower for women compared to men in the Framingham dataset, the measures of
predictive ability, reclassification and clinical utility were both larger for women. The difference in these results was,
in part, due to the larger hazard ratio associated with the additional risk predictor (systolic blood pressure) for
women.
Conclusion: Measures such as the c-statistic and the measures of reclassification do not capture the consequences
of implementing different prediction models. We do not recommend their use in evaluating which new predictors
may be clinically useful in a particular population. We recommend that a measure such as net benefit or EFLY is
calculated and, where appropriate, the measure is weighted to account for differences in the distribution of risks
between the study population and the population in which the new predictors will be implemented.
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Models that calculate the risk of disease are widely used to
aid diagnosis and prognosis [1]. Examples of commonly
used models include the Framingham Risk score for CVD
and the Gail model for breast cancer [2,3]. However, the
predictions provided by these models are not perfect and
ways to improve the predictions are frequently proposed.
One such method is to include additional predictors in the
model [4]. Whether the additional predictors provide bet-
ter predictions and how this is evaluated has been the sub-
ject of numerous articles in recent years [5-8].
If a new predictor is to be added to a prediction model
then the benefits of including this new predictor must
outweigh the costs; the new predictor must demonstrate
clinical utility. Measures of clinical utility that have been
proposed include the net benefit and event free life years
(EFLYs) [6,9]. Several authors have suggested that such
measures of clinical utility be calculated after the new
predictor has demonstrated incremental predictive abil-
ity in terms of either an increase in the c-statistic, the
continuous version of net reclassification improvement
(NRI(>0)) or the categorical NRI [5,10-12]. This staged
approach implies the predictive ability results provide an
indication of the likely clinical utility results.
The c-statistic has been criticised as being insensitive
to the effect of important new predictors [13]. Therefore
it is questionable whether such an insensitive measure is
of use in determining which new predictors should then
be assessed in terms of clinical utility. The NRI(>0) has
been proposed as a better measure of discrimination
than the c-statistic when comparing predictors but how
the NRI(>0) then relates to the clinical utility measures
has not been examined [5]. If the measures of predictive
ability do not correlate with the measures of clinical util-
ity then it is doubtful whether they would be helpful in
deciding which new predictors should be investigated
further.
An additional concern is that these measures may be-
have differently as the mean risk of the population being
studied changes. For example, the c-statistic is largely
unaffected by the mean risk in the population whereas
measures of reclassification may be affected by where the
reclassification cutpoint is set in relation to the distribu-
tion of risk in the population [14]. The categorical NRI
also implicitly weights the reclassification of cases and
non-cases by the prevalence in the sample population
[15]. The impact of changing cutpoints on net benefit has
been examined recently [16], however, less attention has
been paid to the situation where the cutpoint is fixed but
the mean risk varies across the populations studied, a
common situation when new cardiovascular risk predic-
tors are assessed.
In the cardiovascular setting, the application of risk
thresholds for treatment has been widely promoted for anumber of years in guidelines across the world [17-20].
New predictors of cardiovascular disease have then been
assessed using these fixed thresholds but in a wide var-
iety of populations. For example, the Emerging Risk Fac-
tors Collaboration has brought together 104 prospective
population-based studies across a number of countries,
several of which are from North America [21]. The mean
age of these North American cohort studies ranges from
54 to 78, and the percentage of males from 0% to 100%
[6]. This indicates a range of mean risks, and differences
in the distribution of risks, across studies in which the
same threshold for treatment would be applied.
In this paper we examine how the measures of predict-
ive ability (c-statistic, binary-statistic, NRI(0), NRI (with
two cutpoints), binary NRI (at the upper cutpoint)) are
related to the measures of clinical utility: net benefit and
event free life years (EFLY) for assessing the effect of
adding a new predictor to a model. We investigate how
differences in the mean risk between populations affect
these measures using simulated data and also using data
from the Framingham Study where the mean risk of
CVD differs for men and women [22].
Methods
Measures of predictive ability
For each of the measures we have chosen to calculate
them at a common, fixed follow-up time of ten years
consistent with the UK guidelines that apply CVD risk
prediction models [17].
Sensitivity and specificity at ten years, assuming a fixed
cutpoint were calculated using the following formulas.
sensitivity ¼ number true positives
number with event
specificity ¼ number true negatives
number without event
where the numbers of true positives, true negatives and
those with and without an event were estimated using
the Kaplan-Meier estimates of the proportion surviving
at ten years.
Harrell’s c-statistic is a measure of discrimination cal-
culated using the formula –
c ¼ number of concordant pairsþ 0:5  number of tied pairs
total number of usable pairs
Each individual with an event before ten years is
paired with every other person, irrespective of their
event status. A pair is usable if their observed survival
times differ, and the paired person had an event or their
censoring time was greater than the survival time for the
individual with the event. A usable pair is concordant if
the predicted survival time is less for the member of the
pair with the shorter observed survival time. A pair is
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with events after ten years are considered censored at
ten years [23].
The binary area under the ROC curve (or binary c-
statistic) is a measure of discrimination at a particular
cutpoint. It is calculated by averaging the sensitivity and
specificity at that cutpoint when the new marker is
added to the model. We calculated the difference in bin-
ary c-statistic using the formula
difference in binary c−statistic ¼ 0:5 change in sensitivityð
þ change in specificityÞ
Measures of reclassification
NRI(>0) and NRI(with two cutpoints) measure the
amount of reclassification that occurs when the new pre-
dictor is added to a model [24]. The proportion of
events and non-events correctly reclassified (reclassified
up and down, respectively) are adjusted by the propor-
tion of events and non-events incorrectly reclassified.
We calculated the NRI(>0) using the formula –
NRI > 0ð Þ ¼ P eventjupð Þ  nU−P eventjdownð Þ  nDð Þ
n P eventð Þð Þ
þ 1−P eventjdownð Þð Þ  nD− 1−P eventjupð Þð Þ  nUð Þ
n  1−P eventð Þð Þð Þ
where n is the total number of people and the subscripts
U and D indicate those reclassified up and down. The
Kaplan-Meier estimates at ten years among all people,
and those reclassified up or down, provide the probabil-
ities (P).
We calculated the NRI(with two cutpoints) using the
formula –
NRI with two cutpointsð Þ ¼ p^up; events− p^down; events
 
þ p^down; non−events− p^up;non−events
 
where p^:; : is the proportion of events, and non-events,
that are reclassified up, or down. As the data are cen-
sored the number of events and non-events are esti-
mated from the Kaplan-Meier estimates at ten years for
each of the cells in the reclassification table [25].
The binary NRI was also calculated. This has a single
cutpoint which was set as the upper cutpoint from the
NRI(with two cutpoints). The binary NRI is directly re-
lated to the binary c-statistic.
binary NRI ¼ 2  difference in binary c−statistic
Measures of clinical utility
The net benefit provides a measure of the number of
people correctly classified as having the outcome, adjustedfor the number of people incorrectly classified as having
the outcome, where the number of people incorrectly clas-
sified as having the outcome is weighted by the relative
importance of a correct classification compared to an in-
correct classification [26]. This weight is determined by
the threshold probability at which people are classified as
having the outcome. We calculated the Net Benefit using
the formula –








where the number of true positives and false positives
are estimated using the Kaplan-Meier estimates of the
percentage surviving at ten years among those with cal-
culated risks greater than the threshold probability; n is
the total number of people and pt is the threshold that
defines high risk.
The number of event free life years (EFLYs) was esti-
mated using the methods described by Rapsomaniki and
colleagues [6] and is based on the formula.
EFLYs gained per person screened ¼ P B Tð Þ−C Tð Þð Þ
where P is the proportion of those evaluated who are
treated, B(T) is the benefit in terms of event free life
years gained among those treated and C(T) is the costs
for those treated, measured also relative to event free life
years. Briefly, individuals with a calculated risk above a
treatment threshold are assumed to have their risk re-
duced by treatment. This reduction in risk leads to a re-
duction in events and an increase in the total number of
event free life years for the population within a given
time period (here 10 years). Each gain in EFLY is as-
sumed to have a monetary value. However, there are
costs involved in treatment particularly for those who
would not have experienced an event within the time
period. Assuming a particular cost per EFLY, Rapsoma-
niki’s method deducts these costs in terms of EFLYs
from the benefit obtained from the gain in EFLY of those
treated.
As in Rapsomaniki’s paper, we set the reduction in risk
due to treatment at 20% which was based on results
from a meta-analysis [27]. The cost of treatment, in
terms of EFLYs, is calculated assuming that the thresh-
old for treatment is the optimal cutpoint in that benefits
match costs at this point. Rapsomaniki and colleagues
put a monetary value on this cost by relating it to the
cost of one EFLY (£20,000) as proposed by the National
Institute for Health and Clinical Excellence (NICE) [28].
Our main analysis focused on the upper cutpoint of 20%
risk at ten years which is used in the UK CVD prevention
guidelines [17]. We also repeated our analyses using upper
cutpoints of 10% and 50%. The lower cutpoint in the
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arbitrarily set at 5% and 25%, respectively.Simulated data
For our simulations we generated survival times that
followed a Cox-exponential survival model using the for-
mula [29].
T ¼ − log Uð Þ
λ exp β1x1 þ β2x2ð Þ
Where U is a uniform random number between 0 and 1,
λ is the baseline hazard rate which was varied to produce
datasets with mean risks at ten years distributed between
0% and 100%. The variables x1 and x2 each had standard
Normal distributions and were independent of each other.
We carried out separate series of simulations by varying
the coefficient β1 from a hazard ratio of 1.5 per 1 standard
deviation increase (weak baseline model) to 3 (medium
baseline model) to 6 (strong baseline model) and by vary-
ing coefficient β2 of the second covariate to produce haz-
ard ratios of 1.2 (weak predictor), 2 (medium predictor)
and 3 (strong predictor). Note the hazard ratios derived
from the Framingham dataset for the traditional CVD risk
factors of age, SBP and total cholesterol ranged from 1.25
to 2.04, per one standard deviation increase (Additional
file 1: Table S1). Since we have assumed a constant hazard
ratio across simulated datasets that have different mean
risks, the odds ratio calculated for events occurring before
ten years will not be constant across the datasets [30]. The
estimated odds ratio is similar to the hazard ratio if the
mean risk is small, but the odds ratio increasingly overesti-
mates the hazard ratio as the mean risk increases.
We also generated censoring times that followed an
exponential distribution with a 10% risk of being cen-
sored at ten years. If the censoring time was less than
the survival time the observation was considered cen-
sored at the censoring time. The proportion censored
decreased from 10% to approximately 2.5% as the mean
risk increased. Each simulation dataset contained 10,000
observations. We simulated 1,000 datasets for each com-
bination of baseline model and additional predictor.
For each of the simulated datasets the measures of pre-
dictive ability and clinical utility were calculated compar-
ing models without and with the second variable. We then
plotted the proportion of people classified as high risk
(above the upper cutpoint) by each of the two models clas-
sified by the mean calculated risk of an event at ten years
for that dataset. The mean risk was calculated from the
model containing both covariates. We plotted the mea-
sures of predictive ability and clinical utility against the
mean risk and applied a cubic spline smoother.Empirical data
We obtained data from the Framingham Heart Study on
the people included in the analysis that resulted in the
2008 Framingham risk equation [22]. At the initial visit,
blood pressure, serum total cholesterol, HDL, smoking
status, diabetes status and use of anti-hypertensive medi-
cation were recorded using standard methods. All study
participants were free of prevalent CVD at the initial
visit and were under continuous surveillance for the de-
velopment of cardiovascular events and death. Max-
imum follow-up was 12 years.
We fitted two Cox proportional hazards models to the
Framingham dataset consisting of the variables that were
included in the proposed general CVD risk prediction
model [22]. The first model included age, total choles-
terol, high density lipoprotein, smoking status, diabetes
status and use of antihypertensive medication. The sec-
ond model included all of these variables, plus systolic
blood pressure (SBP). We carried out separate analyses
for men and women as the risk of CVD differs between
men and women.
We compared the models without SBP and with SBP
using the following measures: change in c-statistic, binary
c-statistic, NRI(>0), NRI(10%, 20%), binary NRI (20%), net
benefit and the event free life years (EFLY). Ninety-five
percent confidence intervals were calculated for these
measures using 2000 bootstrap samples. We used a treat-
ment cutpoint of 20% for the calculations of the measures
net benefit and EFLYs (and 10%, 20% for the NRI(10%,
20%)) to match current cardiovascular disease (CVD) pre-
vention guidelines [17]. We assumed that for treated people
their risk of CVD would be reduced by 20% based on the
meta-analysis reported in the paper by Rapsomaniki that
introduced the EFLY [6].
Results
Simulated data
The simulation results presented focus on the scenario
where a new predictor with a hazard ratio of 2 per 1
standard deviation (medium new predictor) was added
to a baseline model whose covariate had a hazard ratio
of 3 per 1 standard deviation (medium baseline model)
and the cutpoint of 20% defined high risk. The results
obtained for other combinations of new predictor, base-
line model and cutpoint were similar for the majority of
combinations. We highlight below where important dif-
ferences arose.
In Figure 1 the difference in proportion classified as high
risk (risk greater than 20% at ten years) is shown when a
new predictor with a hazard ratio of 2 per 1 standard devi-
ation (medium new predictor) was added to a baseline
model whose covariate had a hazard ratio of 3 per 1 stand-
ard deviation (medium baseline model). There was a
slightly higher proportion of people classified as high risk
Figure 1 Proportion of people above cutpoint assuming predictions based on the Base model or the Base Model + New Predictor,
assuming a hazard ratio of 2 for the New Predictor. Broken line = Proportion above cutpoint for baseline model. Solid line = Proportion above
cutpoint for baseline model plus new predictor.
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when the baseline model was applied for the majority of
datasets whose mean risk was below the cutpoint. For data-
sets where the mean risk was near or above the cutpoint,
a higher proportion were classified as high risk by theFigure 2 Differences in measures of predictive ability when a new pre
(medium). Legend: Sensitivity,baseline model. Similar results were obtained when the
hazard ratio for the new predictor and the baseline model
were varied. When the new predictor was weak (hazard ra-
tio of 1.2) there was very little difference in the proportions
classified as high risk across all levels of mean risk.dictor (hazard ratio = 2) is added to the baseline model
Specificity. c-statistic binary c-statistic.
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had consistently larger c-statistics than the base model.
The increase in the c-statistic ranged from 0.04 to 0.05
when the new predictor was moderate (hazard ratio of
2). As the mean risk increased there was a small increase
in the difference in the c-statistic. Although in the simu-
lated datasets the hazard ratio was constant as the mean
risk increased, the odds ratio increased. At a mean risk
of 5% the average odds ratio in the simulated datasets
was 2.08, at 10% 2.21, at 25% 2.34, at 50% 2.61 and at
90% 3.14.
Differences in sensitivity increased and then decreased
as the mean risk increased from zero to the cutpoint
(Figure 2). The maximum improvement in sensitivity
with the addition of the new predictor occurred when
the mean risk was approximately half of the cutpoint. At
this point, and for the majority of the range of mean
risks below the cutpoint, specificity was lower with the
addition of the new predictor. The model with the new
predictor had lower sensitivity when the mean risk was
above approximately 1.5 to 2 times the cutpoint and as
the strength of the baseline model increased, the point
at which the model with the new predictor had lower
sensitivity increased. In contrast the difference in specifi-
city increased with mean risk achieving a maximum at
approximately the point when mean risk was double the
cutpoint for a baseline model of medium strength. The
point at which the maximum difference in specificityFigure 3 Reclassification measures and differences in Net Benefit and
added to baseline model (medium strength). Legend: NRI tw
continuous NRI Net Benefit
The NRI measures are plotted against the left vertical axis and the EFLY andwas achieved increased with the strength of the baseline
model, at which point the decrease in sensitivity with
the addition of the new predictor was at its greatest.
The difference in c-binary (which is the average of the
differences in sensitivity and specificity) peaked at two
points before approaching zero as the mean risk increased.
The first peak corresponded to the maximum difference in
sensitivity which happened at approximately half of the cut-
point, and the second corresponded to the maximum dif-
ference in specificity which happened above the cutpoint.
Similar patterns were observed for all combinations of
baseline model and new predictor for each of the mea-
sures: differences in c-statistic, sensitivity, specificity and
binary c-statistic.
The pattern observed for the difference in c-binary
was reflected in the pattern for NRI binary, as these
measures have a direct relationship (Figure 3). The NRI
(10%, 20%) showed a similar pattern in that it reached
two peaks, however the second peak above the cutpoint
was larger than the peak below the cutpoint. As with
NRI binary the NRI(10%, 20%) approached zero as the
mean risk increased. The NRI-continuous, in contrast,
continued to increase with increasing mean risk. As with
the increase observed in the c-statistic, this is due to
underlying odds ratio increasing with increasing mean
risk when the hazard ratio remains constant.
The two measures of clinical utility (difference in Net
benefit and difference in EFLY) showed similar patternsEvent Free Life Years when new predictor (hazard ratio =2) is
o cutpoints, binary NRI
Event Free Life Years (EFLY). Note: This graph has two vertical axes.
Net Benefit are plotted against the right vertical axis.
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creased from zero as the mean risk approached the cut-
point and attained a maximum at approximately the
cutpoint. When mean risk was higher than the cutpoint,
the two measures dropped with the difference in Net
Benefit approaching zero with increasing risk. The dif-
ference in EFLY dropped below zero above the cutpoint
but then approached zero as the mean risk increased.
There was some variation in these patterns depending
on the strength of the baseline model. When the base-
line model was strong (Figure 4) similar results were
obtained for the differences in Net Benefit and EFLY,
however for the NRI measures they initially decreased
for mean risks below the cutpoint. When the baseline
model was weak (Figure 5), the second peak for the NRI
categorical and NRI binary was less pronounced and
tended to be lower than that for the first peak.
We found the same general relationships between the
different measures and the mean risk when the alterna-
tive cutpoints defining high risk of 10% and 50% were
applied.
Figure 6 displays the difference in Net Benefit plotted
against the mean risk for various combinations of base-
line model and new predictor. When the new predictor
was weak the difference in net benefit was minimal at all
levels of mean risk no matter the strength of the baseline
model. The difference in net benefit was higher when a
new predictor was added to a weaker model than whenFigure 4 Reclassification measures and differences in Net Benefit and
added to baseline model (strong). Legend: NRI two cutpoints
NRI Net Benefit Event Fre
measures are plotted against the left vertical axis and the EFLY and Net Beit was added to a stronger model. This held for both
medium and strong new predictors. However, a medium
new predictor when added to a weak model produced a
higher difference in net benefit near the cutpoint than a
strong new predictor when added to a strong model.
Empirical data
There were 3969 men and 4522 women included in the
Framingham dataset. The mean calculated risk of CVD
at 10 years was 15.6% for men and 8.2% for women.
As expected, there was very strong evidence that sys-
tolic blood pressure was related to the risk of CVD after
adjusting for the other risk factors (Table 1). The hazard
ratio (per 20mmHg increase) for systolic blood pressure
was greater for women (1.48) compared to men (1.30).
Among men, both sensitivity and specificity increased
when systolic blood pressure was added to the model,
whereas for women there was an increase in sensitivity
but a decrease in specificity. This is consistent with the re-
sults from the simulations where datasets whose mean risk
was approximately half the cutpoint showed a decrease in
specificity and an increase in sensitivity. There was an in-
crease in all the measures (except the NRI for women) to
assess a new predictor for both men and women (Table 2)
with the increases being greater for women. Although
women had a mean risk lower than men this was compen-
sated for by the greater hazard ratio for systolic blood
pressure among women.Event Free Life Years when new predictor (hazard ratio =2) is
, binary NRI continuous
e Life Years (EFLY). Note: This graph has two vertical axes. The NRI
nefit are plotted against the right vertical axis.
Figure 5 Reclassification measures and differences in Net Benefit and Event Free Life Years when new predictor (hazard ratio =2) is
added to baseline model (weak). Legend: NRI two cutpoints, binary NRI continuous NRI.
Net Benefit Event Free Life Years (EFLY). Note: This graph has two vertical axes. The NRI
measures are plotted against the left vertical axis and the EFLY and Net Benefit are plotted against the right vertical axis.
Figure 6 Difference in Net Benefit for selected combinations of baseline model and new predictor. Legend: Strong baseline +
strong new predictor Medium baseline + strong new predictor. Weak baseline + strong new
predictor. Strong baseline + medium new predictor Medium baseline + medium new predictor.
Weak baseline +medium new predictor. Strong baseline + weak new predictor Medium
baseline + weak new predictor. Weak baseline + weak new predictor. Abbreviations: NRI = Net Reclassification Improvement, NB = Net
Benefit, EFLY = Event Free Life Years.
McGeechan et al. BMC Medical Research Methodology 2014, 14:86 Page 8 of 12
http://www.biomedcentral.com/1471-2288/14/86
Table 1 Hazard ratios for the addition of systolic blood pressure to models predicting CVD for men and women in
Framingham study
Men Women
Base model Base model + systolic blood
pressure




Hazard ratio (95% CI) Hazard ratio
(95% CI)
Hazard ratio (95% CI)
Age (per 10 year increase) 1.94 (1.80, 2.01) 1.80 (1.67, 1.95) 1.83 (1.66, 2.03) 1.56 (1.40, 1.74)
Total cholesterol (per 40 increase) 1.25 (1.17, 1.35) 1.23 (1.15, 1.32) 1.26 (1.16, 1.37) 1.23 (1.13, 1.33)
HDL (per 10 increase) 0.83 (0.77, 0.88) 0.82 (0.77, 0.87) 0.88 (0.82, 0.94) 0.88 (0.83, 0.94)
Hypertensive medication 1.72 (1.41, 2.08) 1.45 (1.18, 1.77) 1.76 (1.41, 2.19) 1.31 (1.04, 1.65)
Current smoker 1.91 (1.64, 2.22) 1.93 (1.66, 2.24) 1.71 (1.40, 2.07) 1.72 (1.42, 2.09)
Diabetes 1.89 (1.53, 2.34) 1.77 (1.42, 2.19) 2.14 (1.60, 2.86) 2.07 (1.55, 2.77)
Systolic blood pressure (per 20mmHg
increase)
1.30 (1.20, 1.41) 1.48 (1.34, 1.62)
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We have described how the measures of predictive ability,
reclassification and clinical utility used to assess a new
predictor in a model depend upon the mean risk of the
population. We have also demonstrated that the reclassifi-
cation measures exhibit a different relationship with the
mean risk than the clinical utility measures. The continu-
ous NRI increases with increasing mean risk; the NRI cat-
egorical with two cutpoints often peaks at two points;
whereas the net Benefit and EFLY peak once close to the
cutpoint and then generally decrease to zero as the mean
risk increases.
In the Framingham Study the mean risk of CVD was
higher for men than for women, and also closer to the
upper cutpoint of 20%. Based on this, we may have ex-
pected the measures of predictive ability, reclassification








Sensitivity 0.575 0.585 0
Specificity 0.729 0.734 0
c-binary 0.652 0.655 0




Net benefit difference (per 1000 evaluated) 44.0 47.5 3
Event Free Life Years difference (per 1000
evaluated)
32.1 34.1 2
Abbreviation: SBP systolic blood pressure.
*There are no separate NRI measures for the baseline and the expanded model. Ththe hazard ratio for systolic blood pressure when it was
added to the model was higher for women compared to
men, and this compensated for the lower mean risk
among women. In a recent review of several new predic-
tors of cardiovascular disease, Paynter and colleagues
have also highlighted that results may differ between
men and women due to differences in effect sizes of new
predictors as well as the strength of the baseline model
and the mean risk in the study sample [31].
In our simulations we observed that as the mean risk
increased the NRI(>0), and the change in the c-statistic,
also increased. In the paper that introduced the NRI(>0)
Pencina suggested that one of the benefits of this meas-
ure was that it was not affected by the event rates in the
population [24]. Our simulations, where we assumed a
constant hazard rate, indicate that the NRI(>0) increases








.010 (−0.17, 0.033) 0.280 0.344 0.064 (0.006, 0.099)
.005 (−0.003, 0.016) 0.921 0.909 −0.013 (−0.020,
−0.003)
.008 (−005, 0.018) 0.601 0.626 0.025 (0.000, 0.041)
.007 (0.003, 0.012) 0.766 0.782 0.016 (0.009, 0.024)
.015 (−0.009, 0.036) 0.051 (0.000, 0.082)
.170 (0.071, 0.267) 0.306 (0.176, 0.419)
.028 (−0.009, 0.063) 0.091(0.010, 0.129)
.5 (−1.6, 7.7) 8.7 12.1 3.3 (−1.3, 6.4)
.0 (−1.8, 5.4) 3.8 7.5 3.6 (−0.4, 6.3)
ey are calculated as an overall measure comparing two models.
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the c-statistic, is unaffected by event rates only if the odds
ratio does not vary. However, as we have demonstrated, if
the hazard ratio is assumed to be the same in populations
with different event rates (a common assumption in co-
hort studies of cardiovascular outcomes) then the NRI(>0)
will increase with increasing event rate.
In our simulations, when the mean risk in the popula-
tion was less than the cutpoint the measures of reclassifi-
cation and clinical utility were generally consistent with
each other and increased as the mean risk increased. How-
ever, beyond this cutpoint the measures diverged. The re-
classification measures continued to increase while the
clinical utility measures decreased, although the NRI bin-
ary and NRI(with two cutpoints) did eventually decrease.
Similar patterns were also observed by Van Calster and
others when they varied the cutpoint and assumed a fixed
mean risk; as the cutpoint moved away from mean risk
the reclassification measures provided a more optimistic
view of the new predictor compared to that provided by
the difference in net benefit [16].
The clinical utility measures, difference in EFLY and
difference in Net Benefit, achieved a maximum value at
approximately the point where the threshold for treat-
ment equaled the mean risk in the population, as ex-
pected [32]. However, we observed a divergence in the
clinical utility measures in our simulations as the mean
risk increased. This is attributable to differences between
the two measures in terms of how benefits and costs are
counted and the weights given to benefits and costs in
populations with different mean risks.
When a new predictor is added to a model, the differ-
ence in EFLY is measured in terms of event free life
years. An event free life year gained has the same value
whether it occurs in a high risk or low risk population.
In contrast, the difference in Net Benefit is measured in
units of true positives, adjusted for false positives, with
the weighting of false positives relative to true positives
determined by the cutpoint defining high risk. However,
the actual value of a true positive will differ in popula-
tions with different mean risks since the number of
event free life years gained will be greater for an individ-
ual from a high risk population compared to a low risk
population. Also, a false positive will have a greater cost
in a low risk population than a high risk population as
the survival time, and hence, treatment time, will be
greater.
Although there are issues in using the Net Benefit
when accounting for costs and benefits over a specific
time period, there are also issues in the calculation of
costs and benefits for the EFLY. Possible heterogeneity
in treatment effects across patient subgroups is not
accounted for in the EFLY. Also, the calculation of the
EFLY assumes that the chosen cutpoint is the ‘optimal’cutpoint in that costs equal benefits at this point; the cost
of treatment, in terms of event free life years, is then cal-
culated based on this assumption. Rapsomaniki and col-
leagues acknowledge that many factors, other than the
costs and benefits they account for in their EFLY calcula-
tions, are considered when a particular cutpoint is chosen
[6]. However, their assumption avoids the problem of an
irrational choice of cutpoint resulting in a poorer model
being favoured [6].
In previous papers the relationship between choice of
cutpoint and the measures of reclassification and the dif-
ference in Net Benefit has been described when the mean
risk in the population is fixed [14,16,33]. We observed
similar results when the mean risk in the population varies
but the cutpoint is fixed. The scenario we have described
is the one more commonly encountered in the evaluation
of new predictors of cardiovascular events. For example,
the Emerging Risk factor Collaboration (EFRC) brings to-
gether several cohort studies from the same country which
have different mean risks but where the same guidelines
and cutpoints for defining high risk would apply. As each
of the measures we have examined are in some way af-
fected by the mean risk in the study population this must
be taken into account when comparisons are made be-
tween different studies whose mean risk varies, or when
the mean risk in the study population differs from the
population in which a new predictor will ultimately be
implemented.
A number of methods have been proposed to allow for
these differences. Where the study data arise from a
matched case control study Pepe has proposed a method
for calculating an adjusted c-statistic that takes into ac-
count the greater similarity in risk between cases and con-
trols that arises from matching [34]. The ERFC applied
age-sex specific measures of reclassification observed in
their study population to the standard European popula-
tion to estimate the amount of reclassification that would
occur in this standard population [35,36]. However, this
relies upon having a large enough study population to pro-
vide reliable estimates of reclassification in each age-sex
stratum. If the data arise from a case control study, Rous-
son suggests reweighting the proportions of cases and
controls to match the proportions found in the parent
population [37].
Conclusion
There have been a number of recent recommendations
regarding which measures of predictive ability should be
reported [5,10,11]. Measures such as the c-statistic and
the measures of reclassification do not capture the con-
sequences of implementing a prediction model. Hence,
we do not recommend their use in evaluating which
new predictor may prove to be clinically useful in a par-
ticular population as these measures assess model fit
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http://www.biomedcentral.com/1471-2288/14/86rather than clinical utility. We recommend that a measure
such as net benefit is calculated and the results adjusted to
allow for the difference in the mean risk between the study
population and the population in which the new predictor
will be implemented. If benefits and costs are to be mea-
sured over a specific time period a measure such as the
EFLY should be used which accounts for the different
costs and benefits that would be accrued over time in pop-
ulations with different mean risks.
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